Senti Biosciences, Inc. announced plans to streamline its business operations, including reducing its workforce by approximately 37%, to enable increased focus on SENTI-202, a first-in-class Logic Gated investigational cell therapy for the treatment of acute myeloid leukemia.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.377 USD | -0.26% | +0.53% | -42.73% |
1st Jan change | Capi. | |
---|---|---|
-42.73% | 17.28M | |
+8.63% | 114B | |
+13.17% | 107B | |
-12.76% | 22.22B | |
-2.42% | 21.28B | |
-5.24% | 18.8B | |
-7.19% | 17.51B | |
-39.93% | 17.17B | |
+6.67% | 14.14B | |
+33.90% | 12.2B |
- Stock Market
- Equities
- SNTI Stock
- News Senti Biosciences, Inc.
- Spark Therapeutics, Inc. Announces Workforce Reduction